In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease
Rs. 40 cr buyback, 200% dividend announced
The capital will be deployed to deepen AI-driven personalisation capabilities, expand its dark store network, and build a strong offline retail presence
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The approval was driven by data from the Phase III TULIP-SC trial
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Subscribe To Our Newsletter & Stay Updated
